Non Small Cell Lung Cancer Clinical Trial
Official title:
Effect of Copper Transporter-1 Genetic Polymorphism on Platinum Based Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients
Study the effect of genetic polymorphism in the membrane copper transporter 1 protein [CTR1;
encoded by the solute carrier family 31 member 1 gene (SLC31A1 gene)] and its genetic
expression levels on the clinical outcome of cisplatin-based regimen used in the treatment of
Non-Small Cell Lung Cancer (NSCLC) in terms of :
- Treatment response : partial response (PR) / complete response (CR) and Progression-free
survival (PFS)
- Treatment resistance : stationary disease (SD) or progressed disease
- Frequency and severity of regimen related toxicity
The cisplatin-based regimen is an effective treatment for advanced NSCLC, showing significant
beneficial outcomes such as prolong survival, improve clinical symptoms, and improve quality
of life (QOL) . Although platinum-based therapy shows several benefits, but the five-year
survival rate still less than 20%.
Pt resistance is an inevitable occurrence with rare exception. Aside from germ cell tumors,
metastatic solid tumors are generally thought to be incurable with cytotoxic chemotherapy due
to the development of resistance and subsequent disease progression.
Despite the multifactorial nature of Cisplatin resistance, intracellular accumulation of Pt
appears to be a major source of drug resistance . Reduced intracellular drug accumulation is
one of the most consistently identified features of cisplatin-resistant cells.
Many evidences indicated that alteration of copper transporter protein 1 (CTR1) which is the
major plasma membrane transporter responsible for platinum uptake, was associated with
platinum sensitivity and toxicity.
Genetic polymorphisms of CTR1 also have effects to platinum treatment response. Therefore,
CTR1 might be a potential prognostic factor for survival in cancer patients underwent
chemotherapy and a treatment target for overcoming platinum resistance.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
| Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
| Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
| Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
| Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
| Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
| Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
| Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |